about
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trialComparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the IntergrouIntravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial.Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone duVTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-rRole of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experienceIMWG consensus on maintenance therapy in multiple myeloma.Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?The translocation t(4;14) can be present only in minor subclones in multiple myelomaChromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.Frontline treatment of multiple myeloma in elderly patients.Frontline treatment in elderly patients with multiple myeloma.Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myelomaContinuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma.Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
P50
Q28252396-365045C4-D9EE-4499-9BA4-F611D48E5D66Q33340726-3D005B4C-E34C-4FD6-A2DB-8C9C95972E4CQ33340776-11B1C54C-AB8A-4C90-929E-A266619B77FAQ33416427-3595A8D3-4231-48ED-A91E-CA74FD4163A3Q33430928-19F53184-9DE5-4A33-8CB4-9F042980186DQ33931651-5B21BB85-D8C4-47EE-AEF7-7CB9D072E823Q34372086-D900FCF3-F32A-466F-A75F-36E6ED7E45FDQ34574044-FFEAACBC-6908-4F78-AF28-E1DB5E352BE9Q34596711-5F546ED6-E87D-456B-AEAF-1C780408CA29Q35180069-84D4D02C-D696-44F0-96DB-EEE34D89F81DQ35220653-1784917D-5764-4F2A-92F7-00F2A28A3217Q35876966-92CBF802-8EB3-4AEB-8BE9-EE1CACF37B43Q35930659-7DC09EF1-58D6-4677-A704-2F294682BE22Q36382187-64658E6C-4FE8-4141-B577-1AFAAD661504Q36890185-86BD5AF9-5BC8-4F9C-B843-91F708A051FAQ37033951-336B2C68-A1DF-4A68-8229-1E33C3BE09BDQ37190134-209C0DF4-1DE1-4518-940E-B84BFC281F6EQ37457285-0ABEB0EC-A7A2-432D-9D7D-948825F84749Q37528072-3375DC46-8CBE-48EA-BD88-EC9D02F22E7FQ37664019-D3AD31E1-3B62-4A5B-8144-795E4DD63458Q38248444-0432DD07-7675-4238-A874-92B800CC87BFQ38414744-2D3EC604-526E-4F48-A151-3A7ED2EBF88FQ38662385-37E6D765-9839-4A21-A527-104C2F91A363Q39062058-109AB92D-5E01-444F-8DB2-45FA17D94ABEQ39485433-E7C0D9FF-90CE-42B4-812C-96949E6DEA0C
P50
description
onderzoeker
@nl
name
Cyrille Hulin
@ast
Cyrille Hulin
@en
Cyrille Hulin
@es
Cyrille Hulin
@sl
type
label
Cyrille Hulin
@ast
Cyrille Hulin
@en
Cyrille Hulin
@es
Cyrille Hulin
@sl
prefLabel
Cyrille Hulin
@ast
Cyrille Hulin
@en
Cyrille Hulin
@es
Cyrille Hulin
@sl
P106
P21
P31
P569
2000-01-01T00:00:00Z